These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21985997)

  • 21. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
    Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
    Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
    López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
    Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.
    Akizawa T; Ohashi Y; Akiba T; Suzuki M; Nishizawa Y; Ogata E; Slatopolsky E; Kurokawa K
    Ther Apher Dial; 2004 Dec; 8(6):480-91. PubMed ID: 15663548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism.
    Park CW; Oh YS; Shin YS; Kim CM; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
    Am J Kidney Dis; 1999 Jan; 33(1):73-81. PubMed ID: 9915270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.
    Yuan F; Chen X; Wang C; Li Z; Liu H
    Blood Purif; 2018; 45(1-3):73-78. PubMed ID: 29216631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
    Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
    Vlassopoulos D; Noussias C; Revenas K; Hadjilouka-Mantaka A; Arvanitis D; Tzortzis G; Hadjiconstantinou V
    Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH; Chiang SS; Tsai SC; Chang CC; Wu SC; Shieh SD; Huang TP
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):319-24. PubMed ID: 8087705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
    Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A
    Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis.
    Kim HW; Park CW; Shin YS; Kim YS; Shin SJ; Kim YS; Choi EJ; Chang YS; Bang BK
    Nephron Clin Pract; 2006; 102(1):c21-9. PubMed ID: 16166802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
    Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
    Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.
    Chen H; Cui Y; Xing C; Purrunsing Y; Zha X; Shen C; Zeng M; Yang G; Yu X; Zhang L; Jiang Y; Shen Z; Ma H; Yin C; Li Y; Wang N
    Int Urol Nephrol; 2018 Dec; 50(12):2279-2288. PubMed ID: 30361964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
    Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
    Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.
    Doi S; Yorioka N; Usui K; Shigemoto K; Harada S
    Intern Med; 2003 Oct; 42(10):955-9. PubMed ID: 14606707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.